

Using an Immunization Information System for Assessment, Feedback, Information, Exchange (AFIX)

New York City
Department of Health and Mental Hygiene
Bureau of Immunization

Amy Metroka, Karen Fernandez, Vikki Papadouka, Melissa Mickle-Hope, Jane R. Zucker

American Immunization Registry Association National Meeting,
October, 2013

New York City (NYC) and the Vaccines for Children (VFC) Program

- 8.3 million people - 1.9 million are 0-18 yrs
 - ~74% of 0-18 yr-olds eligible for publicly funded vaccines
 - ~66% VFC
 - ~1% 317 (underinsured, vaccinated at other than FQHCs)
 - ~7% SCHIP
- 88% (1,530) of all pediatric provider sites (1,737) enrolled in VFC
- ~3.3 million publicly funded vaccine doses costing ~\$138 million distributed in NYC annually

Citywide Immunization Registry (CIR)

- NYC's Immunization Information System (IIS)
 - State, City reporting mandate for immunizations administered to patients 0-18 years of age
 - ~ 4.9 million patient records
 - ~ 65 million immunizations
- In 2006, we linked CIR reporting to VFC distribution
 - Created CIR-generated VFC doses administered report (DAR):
doses reported to CIR in year / # doses received from VFC in year
 - Providers with DAR < 90% subject to a reduction of order
 - CIR reporting increased 70%, leading to more complete data
 - Coverage is within confidence intervals of Natl Imm Survey (NIS)
 - Transitioned to using CIR for 100% of AFIX from 2006-2010

AFIX in NYC

- AFIX visits conducted among VFC sites to improve coverage
 - Prioritize sites with childhood series coverage < 90% and not visited in previous year
 - Conduct AFIX among 30% of enrolled VFC sites
- Before 2006, AFIX based on chart review
 - Piloted AFIX using IIS at end of 2006
 - Transitioned to 100% AFIX through IIS in July 2010
- In 2008, merged AFIX and VFC field ops teams
 - Conducts combined AFIX and VFC compliance site visits
 - ~ 2/3 of VFC site visits include AFIX

Why Transition to Using IIS for AFIX?

- Consumes less time and resources than chart review
 - Less disruptive to provider's practice
 - AFIX-IIS conducted in ½-1 day vs. 2-3 days
 - No data entry
 - Helps improve completeness of IIS data
 - Further incentive for providers to report to IIS
- Allows for assessment of all patients in age group (instead of sample)
- Facilitates expansion of age groups

Changes to Facilitate Use of IIS for AFIX

- Developed user friendly tool: Web Up-To-Date (UTD) Application
- Trained field staff to run Web UTD by site:
 - Summary report of coverage
 - Lists of children not UTD
 - % of invalid doses (age, interval)
- Improved patient de-duplication in IIS
- Added fields to IIS Online Registry: Moved or Gone Elsewhere (MOGE) and Disease History

IIS Online Registry

MOGE Field

Please enter the fields your practice has not recently updated.

Patient Information

First Name: MICKEY
Last Name: MOUSE
DOB: 01 / 01 / 2001 (mm/dd/yyyy)
Gender: ☒ M ☐ F

Alternate First:
Middle Name:
Alternate Last:

Medical Rec. No.:
Medicaid No. (A#####A):

Mom DOB: / / (mm/dd/yyyy)
Mom First Name:
Mom Maiden Name:

House No. / St. / Apt. No.: 1234 ANYWHERE
City / State / ZIP: MAGIC KIN NY 10705
Telephone:

Is patient active?
☒ Yes, patient is currently in my practice
☐ No (select reason)
☐ Not in my practice (Gone elsewhere)
☐ Not in NYC (Moved)
☐ Patient deceased

Clear Continue

Disease History Field

Use this page to review or indicate disease immunity.
When complete, you may return to the patient's [immunization and lead history](#).

Report Immunity

Immunity	Immunity by:	Test/Disease Date:
Varicella:	<input type="text"/>	<input type="text"/> / <input type="text"/> / <input type="text"/> (mm/dd/yyyy) <small>When reporting Varicella disease and exact date is unavailable, estimate month and year.</small>
Laboratory Test Demonstrating Immunity:	<input type="checkbox"/> Hepatitis A IgG <input type="checkbox"/> Hepatitis B anti-HBs (Hepatitis B surface antibody) <input type="checkbox"/> Measles IgG <input type="checkbox"/> Mumps IgG <input type="checkbox"/> Rubella IgG	<input type="text"/> / <input type="text"/> / <input type="text"/> (mm/dd/yyyy)

Clear Confirm

Immunity Reported

Disease	Immunity by:	Test/Disease Date	Reported On	
Measles	Titer	06/15/2007	08/30/2013	edit / delete
Rubella	Titer	06/15/2007	08/30/2013	edit / delete
Mumps	Titer	06/15/2007	08/30/2013	edit / delete
Varicella	History	03/31/2004	08/30/2013	edit / delete

Steps for Implementing AFIX Using IIS

AFIX - Assessment

- Field staff run immunization coverage through IIS Web UTD (instead of Co-Casa) before site visit
 - All patients in age range included
 - Age groups in 2012:
 - 19 to 35 months
 - 13 years
 - Identify and merge duplicate patient records
 - Re-run coverage after records are merged
 - Generate list of children not UTD for recall
 - Identify patterns of noncompliance with immunization schedule based on IIS clinical decision support

AFIX - Feedback

- Visit provider to conduct feedback sessions covering:
 - IIS-generated immunization coverage levels and areas of noncompliance with schedule
 - Recommendations for improving coverage, e.g.:
 - Evaluate patient immunization status at each visit based on age and interval not just vaccine dates
 - Use the IIS to obtain patient immunization history and recommendations of immunizations due now, in future
 - Recall and immunize children not UTD

AFIX - Incentives

- Give providers recall lists at site visit
- Send follow-up report to show provider results of assessment 3 to 4 months later
 - Sites with $< 90\%$ coverage and ≥ 25 patients in either age group
- Honor providers for high coverage
 - In person, at Childhood Coalition Meeting
 - Post name on BOI Web site
 - 2012 Criteria:
 - $\geq 90\%$ for 4 DTaP:3 polio:1 MMR:4* Hib:3 Hep B :1 varicella (4:3:1:4:3:1) among 19-35 mo-olds
 - $\geq 80\%$ for 1 Td/Tdap:1 Mening among 13 year-olds
 - $\geq 90\%$ VFC Doses Administered Report (DAR)

AFIX - eXchange

- At site visit, exchange information to facilitate improvement in coverage
 - Follow the ACIP Schedule
 - Use IIS reminder/recall system
 - Use Web sites: www.immunize.org and www.cdc.gov for current VISs, other information
- Refer providers to IIS outreach staff
 - Training on IIS Online Registry reminder/recall system
 - Troubleshooting to resolve IIS reporting problems

Web UTD Application: Parameter-Driven Tool to Run Coverage by Facility

The Web Up-To-Date (UTD) application is an internal tool developed to run immunization coverage rates by site based on valid doses administered.

The screenshot shows a web browser window titled "Web UTD - Logon (PROD) - Microsoft Internet Explorer provided by HEALTH". The address bar displays "http://10.131.56.218/web-utd-prod/app". The page has a blue header with the text "Web UTD - Logon (PROD)". Below the header, the main content area is titled "Patient/Facility Up-to-Date Utility". On the left, there is a blue square logo with the letters "utd" in white. To the right of the logo, the text "User Login" is displayed with a small padlock icon. Below this, there are two input fields: "User ID:" with the text "kfernand" and "Password:" with a masked password "*****". A "Login" button is positioned below the password field. At the bottom of the page, a blue footer bar contains the text "© 2006 - Citywide Immunization Registry, NYC Department of Health". The Windows taskbar at the bottom shows the Start button, a taskbar with "Inbox - Microsoft Outlook" and "Web UTD - Logon (PR...", and a system tray with a clock showing "5:12 PM" and a "Local intranet" icon.

Web UTD - Logon (PROD) - Microsoft Internet Explorer provided by HEALTH

File Edit View Favorites Tools Help

Back Forward Stop Home Search Favorites Refresh Print Mail Stop

Address http://10.131.56.218/web-utd-prod/app Go Links

Web UTD - Logon (PROD)

Patient/Facility Up-to-Date Utility

utd

User Login

User ID: kfernand

Password: *****

Login

© 2006 - Citywide Immunization Registry, NYC Department of Health

Done Local intranet

Start Inbox - Microsoft Outlook Web UTD - Logon (PR... 5:12 PM

Parameter-Driven

- Specify Facility
- Facility population inclusion criteria: based on child receiving last series shot at that facility
 - After a certain age for each patient
 - 1 yr (361 days) for 19-35 mo-olds
 - 9 yrs for (3,287 days) 13 yr-olds
- Specify age range of population assessed
- Review date: date coverage is run - it can be run as of a date in the past
- Specify number of antigens for UTD

Web UTD - New Job (Step 3) (PROD)

New Job Wizard

Step 1 Step 2 **Step 3** Step 4

Select all vaccine groups to include:

<input type="text" value="3"/>	100 (HepB)	
<input type="text" value="4"/>	200 (DTP)	
<input type="text" value="0"/>	Tdap (115)	
<input type="text" value="0"/>	Td (09, 113)	
<input type="text" value="0"/>	Tdap (115) / Td (09, 113)	
<input type="text" value="4"/>	300 (Hib)	<input checked="" type="checkbox"/> ICE override
<input type="text" value="0"/>	Merck Hib (49, 51)	
<input type="text" value="0"/>	non-Merck Hib	
<input type="text" value="3"/>	400 (Polio)	
<input type="text" value="1"/>	500 (MMR)	
<input type="text" value="1"/>	600 (Varicella)	
<input type="text" value="4"/>	700 (Pneumo. Conjugate)	<input checked="" type="checkbox"/> ICE override
<input type="text" value="0"/>	720 (Pneumo. Polysaccharide)	
<input type="text" value="0"/>	800 (Influenza)	
<input type="text" value="0"/>	810 (HepA)	
<input type="text" value="0"/>	820 (Rotavirus)	
<input type="text" value="0"/>	830 (Meningococcal)	
<input type="text" value="0"/>	MCV4 (114)	
<input type="text" value="0"/>	MPSV4 (32)	
<input type="text" value="0"/>	MCV4 (114) / MPSV4 (32)	
<input type="text" value="0"/>	840 (Human Papillomavirus)	
<input type="text" value="0"/>	890 (H1N1 Influenza)	

Review Date
(Immunization):

Web UTD Output Files

- File with summary statistics
 - # of children assessed
 - # and % of children UTD for specified series and each antigen in the series
 - # of invalid shots
- File with list of children for recall
 - Names of children missing at least one shot from specified series
 - Type and dose number of shot missing

Immunization Coverage Feedback Report, 2012 19-35 Month-Olds

Series/Antigens	Assessment (N=47)
4:3:1:4:3:1	71%
4 DTaP	76%
3 Polio	95%
1 MMR	95%
Hib Full Series (Age/Interval-Adjusted)	95%
3 Hep B	90%
1 Varicella	95%
PCV Full Series (Age/Interval Adjusted)	90%
Hep A (2 doses)	29%

Recall List, 2012

Facility: 7777X01													
Minimum DOB: 08/01/2010													
Maximum DOB: 12/31/2011													
Review Date (Immunization): 08/15/2013													
Date Produced: 08/15/2013 16:08:40													
FACILITY CODE	SELECTION METHOD	VACCINE GROUP	TOTAL PATIENTS (EXCLUDING MOGES)	TOTAL PATIENTS (INCLUDING MOGE)	TOTAL NUMBER OF MOGES	COUNT OF PATIENTS WITH AT LEAST ONE INVALID	COUNT OF INVALID SHOTS-THIS FACILITY	COUNT OF INVALID SHOTS-ANY FACILITY	# OF PTs WITH MMR < 1 YEAR OF AGE	# OF PTs WITH VARICELLA < 1 YEAR OF AGE	# OF PTs WITH MMR AND VARICELLA < 28 DAYS APART	# OF PTs WITH 3rd HEPB < 6 MONTHS OF AGE	# OF PTs WITH 4th DTaP < 4 MONTHS AFTER 3rd DOSE
2015X01	LAST SERIES SHOT	ALL	225	229	4	2	4	4	0	0	0	0	0
2015X01	ANY SERIES SHOT	ALL	254	286	32								
Percent UTD (last series shot)													
431431 Series Percent UTD		96.40%											
4 DTaPs:		96.90%											
3 Polios:		100.00%											
1 MMR:		100.00%											
4 Hibs (Full Hib Series):		97.80%											
3 Hep Bs:		100.00%											
1 Varicella:		100.00%											
4 PCV (Full PCV Series):		97.80%											
2 Hep A:		86.70%											
Detailed List of Patients Not UTD (last series shot)													
COUNT	CIR NUMBER	LAST NAME	FIRST NAME	DOB	GENDER	MEDREC	SERIES DUE	NOT UTD BUT NOT YET DUE SERIES	MMR < 1 YEAR OF AGE	VARICELLA < 1 YEAR OF AGE	MMR AND VARICELLA < 28 DAYS APART	3rd HEPB < 6 MONTHS OF AGE	4th DTaP < 4 MONTHS AFTER THE 3rd
***The following patients are not UTD on the series:													
1	1111	A	a	10/11/2011	F	11		HepA-2	N	N	N	N	N
2	1112	B	b	10/12/2011	M	12	HepA-2		N	N	N	N	N
3	1113	C	c	5/25/2011	M	13	HepA-2		N	N	N	N	N
4	1114	D	d	11/27/2011	M	14		HepA-2	N	N	N	N	N
5	1115	F	e	9/17/2011	F	15	HepA-2		N	N	N	N	N
6	1116	G	f	6/23/2011	M	16	HepA-2		N	N	N	N	N
7	1117	H	g	12/16/2011	F	17	DTP-2, HepA-2		N	N	N	N	N
8	1118	I	h	5/28/2011	M	18	HepA-2		N	N	N	N	N
9	1119	J	i	12/21/2011	F	19	DTP-4, Hib-4*, Pneumo Conj-4, HepA-2		N	N	N	N	N
10	1120	K	j	11/9/2010	M	20	Pneumo Conj-4		N	N	N	N	N
11	1121	L	k	11/5/2011	F	21	HepA-2		N	N	N	N	N
12	1122	M	l	11/7/2011	F	22		HepA-2	N	N	N	N	N
13	1123	N	m	10/8/2011	M	23	HepA-2		N	N	N	N	N
14	1124	O	n	10/30/2011	M	24	DTP-4	HepA-2	N	N	N	N	N

Immunization Coverage Feedback Report, 2012

13 Year-Olds, Males and Females

Series/Antigens	Total Children Assessed	Percent UTD
1 Td/Tdap:1 Mening	267	91%
1 Td/Tdap	267	94%
1 Mening	267	93%

Immunization Coverage Feedback Report, 2012

13 Year-Olds, Males and Females Separately

Series/Antigens	Total Children Assessed	Percent UTD
1 Td/Tdap:1 Mening:1 HPV, Males	120	36%
1 Td/Tdap:1 Mening:3 HPV, Males	120	21%
3 HPV, Males	120	28%
1 Td/Tdap:1 Mening:1 HPV, Females	147	56%
1 Td/Tdap:1 Mening:3 HPV, Females	147	43%
3 HPV, Females	147	45%

Coverage After Recall/ Follow-Up


Recall / Follow-Up, 2012

19-35 Month-Olds

Coverage Comparison: At Assessment (N=28,375) vs. Recall/Follow-up (N=28,614)


237 Provider Sites

Average of 5.7 Months Later



Recall / Follow-Up, 2012

13 Year-Olds
227 Provider Sites



AFIX: 2012

- Total of 491 provider sites received AFIX
 - 34% of enrolled, active VFC provider sites (1,454)
- Most sites had AFIX for 2 age groups
- Total of 83,024 children assessed
 - 50,570 were 19-35 mo-olds; 32,454 were 13-yr-olds
 - Estimate these numbers are ~ 1/3 of total population in each of the 2 age groups

2006 Versus 2012

	2006 (Chart Review)	2012 (IIS)
Number of sites assessed	197 (15% of VFC sites)	491 (34% of VFC sites)
Number of children assessed	8,001*	83,024**

* 24-35 month olds

**50,570 19-35 month-olds; 32,454 13 -year-olds

Conclusions

- AFIX through IIS allowed us to improve our efficiency by:
 - Increasing # of provider sites assessed
 - Increasing # and age groups of children assessed
 - Age groups can be added quickly
 - Additional single antigens and series can be added quickly
 - Increasing coverage at follow-up in large populations

Next Steps I

- Enhancements in 2013
 - Added 4 PCV to series for 19-35 mo-olds
 - Expanded adolescent group: 13-17 yr-olds
 - Assessing males, females separately for 1, 3 HPV
 - Follow-up with sites with <90% coverage and 10 patients in either age group (was 25 patients in 2012)

Next Steps II

- Enhancements planned for 2014
 - Assess males, females combined for adolescent series and 1, 3 HPV
 - Add 1 HPV to adolescent series for Honor Roll: 80% for 1:1:1 in addition to other criteria

Special Thanks

- Paul Schaeffer, Deputy Director, CIR
- Mikhail Golender, MPH, Data Coordinator, PQA